[en] In this review, two types of soft-tissue involvement in multiple myeloma are defined: (i) extramedullary (EMD) with haematogenous spread involving only soft tissues and (ii) paraskeletal (PS) with tumour masses arising from skeletal lesions. The incidence of EMD and PS plasmacytomas at diagnosis ranges from 1·7% to 4·5% and 7% to 34·4% respectively. EMD disease is often associated with high-risk cytogenetics, resistance to therapy and worse prognosis than in PS involvement. In patients with PS involvement a proteasome inhibitor-based regimen may be the best option followed by autologous stem cell transplantation (ASCT) in transplant eligible patients. In patients with EMD disease who are not eligible for ASCT, a proteasome inhibitor-based regimen such as lenalidomide-bortezomib-dexamethasone (RVD) may be the best option, while for those eligible for high-dose therapy a myeloma/lymphoma-like regimen such as bortezomib, thalidomide and dexamethasone (VTD)-RVD/cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) followed by SCT should be considered. In both EMD and PS disease at relapse many strategies have been tried, but this remains a high-unmet need population.
Precision for document type :
Review article
Disciplines :
Hematology
Author, co-author :
Rosiñol, Laura
Beksac, Meral
Zamagni, Elena
Van de Donk, Niels W. C. J.
Anderson, Kenneth C.
Badros, Ashraf
Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Mitsiades CS, McMillin DW, Kippel S, Hideshima T, Chauhan D, Richardson PG, et al. The role of bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007;21:1007–34.
Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25:325–34.
Ghobrial I. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120:20–30.
Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–12.
Wu P, Davies F, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma. 2009;50:230–5.
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1,003 consecutive patients. Ann Oncol. 2009;21:325–30.
Bladé J, Lust J, Kyle RA. Immunoglobulin D multiple myeloma: presenting features response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.
Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93:345–51.
Buthani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1–20.
Gagelmann N, Eikema DJ, Iacobellis S, Koster L, Nahi H, Stoppa AM, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malingancies Working Party of the EBMT. Haematologica. 2018;103:890–7.
Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4.
Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843–50.
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is overrepresented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:4761–7.
Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide in extramedullary myeloma. Leukemia. 2011;25:906–8.
Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169:851–8.
Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54:1459–64.
Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127:971–6.
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819–23.
Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, et al. Diagnosis, treatment and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:1–10.
Churg J, Gordon AJ. Multiple myeloma: lesions of the extra-osseous hematopoietic system. Am J Clin Pathol. 1950;20:934–45.
Hayes DW, Bennett WA, Heck FJ. Extramedullary lesions in multiple myeloma: review of the literature and pathologic studies. AMA Arch Pathol. 1952;53:262–72.
Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma: a review of 57 autopsied cases. Cancer. 1969;23:167–74.
Bartel B, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.
Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8.
Fernández de Larrea C, Jiménez R, Rosiñol L, Giné E, Tovar N, Cibeira MT, et al. Pattern of relapse and progression after autologous stem cell transplantation as upfront therapy in multiple myeloma. Bone Marrow Transplant. 2014;49:223–7.
Pérez-Simón JA, Sureda A, Fernández-Avilés F, Sampol A, Cabrera JR, Caballero D, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20:542–5.
Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2004;34:1057–65.
Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 2004;34:1057–65.
Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, Garcia-Larana J, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica. 2002;87:609–14.
Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F, et al. Intensive therapy for multiple myeloma in patients younger than 60 years: long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica. 2006;91:1228–33.
Vincent L, Ceballos P, Plassot C, Méniane JC, Quittet P, Navarro R, et al. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J. 2015;5:e341.
Rosiñol L, Jiménez-Segura R, Cibeira MT, Fernández de Larrea C, Bladé E, Tovar N, et al. Plasmacytomas in multiple myeloma: 45-years experience from a single institution. Clin Lymphoma Myeloma Leuk. 2017;17:e107.
Moreau P, Polliack A. Extramedullary multiple myeloma: extraosseous relapse is extra “bad news”, but why? Leuk Lymphoma. 2013;54:1349–50.
Bladé J, Fernández de Larrea C, Rosiñol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol. 2015;169:763–5.
Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57:2071–6.
Fassas AB, Ward S, Muwalla F, Van Hemert R, Schluterman K, Harik S, et al. Myeloma of the central nervous system: strong association with unfavourable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45:291–300.
Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol. 2007;80:1–9.
Schluteman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004;61:1423–9.
Chamberlain MC, Glanz M. Myelomatous meningitis. Cancer. 2008;112:1562–7.
Gozzetti A, Cesare A, Lotti F, Rossi D, Palumbo A, Petrucci MT, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118:1574–84.
Jurcyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91:575–80.
Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, et al. Central nervous system involvement in multiple myeloma: long-term survival can be achieved with radiation, intrathecal chemotherapy and immunomodulatory agents. Br J Haematol. 2013;162:483–8.
Reseblum MD, Bredeson CN, Chang CC, Rizzo JD. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol. 2003;72:274–7.
Fernández de Larrea C, Rosiñol L, Cibeira MT, Rozman M, Rovira M, Bladé J. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol. 2010;85:448–51.
Moreno D, Setoain X, Bladé J, Rosiñol L. Extramedullary plasmacytoma over the scar from long-lasting past surgery as presenting feature of multiple myeloma. Arch Clin Biomed Res. 2020;4:766–74.
Rosiñol L, Fernández de Larrea C, Bladé J. Extramedullary myeloma spread triggered by surgical procedures: an emerging entity? Acta Haematol. 2014;132:36–8.
Yata K, Yaccoby S. The SCID-rab model: a novel in vitro system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18:1891–7.
Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33:1137–40.
Cerny J, Fadare O, Ll H, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008;81:65–9.
Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.
Chang H, Barlett E, Patterson B, Chen I, Yi QL. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol. 2005;129:539–41.
Sheth N, Yeung J, Chang H. P53 nuclear accumulation is associated with extramedullary progression on multiple myeloma. Leuk Res. 2009;33:1357–60.
Chang H, Sloan S, Li D, Stewart K. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13 (p53) deletions. Br J Haematol. 2014;127:280–4.
López-Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84:359–61.
Besse L, Sedlarikova L, Greslikova H, Kupsta R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97:93–100.
Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Similar incidence of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolysis of patients with multiple myeloma. Anticancer Res. 2012;32:2031–4.
Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87–94.
Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286–91.
Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 2012;91:1031–7.
Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: results of a randomized phase III PETHEMA/GEM study. Blood. 2012;120:1589–96.
Dimopoulos MA, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23:1545–56.
Dimopoulos MA, Kyle RA, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report on the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117:4701–5.
Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–64.
Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159:499–513.
Zamagni E, Nanni C, Tachetti P, Pantani L, Marzocchi G, Zannetti B, et al. Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:e101–4.
Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET Use). Eur J Nucl Med Mol Imaging. 2016;43:414–21.
Lu YY, Chen JH, Lin WY, Liang JA, Wang HY, Tsai SC, et al. FDG-PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and metaanalysis. Clin Nucl Med. 2012;37:833–7.
Van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. FDG positron emission tomography in assessment of myeloma-related bone disease. Cancer. 2012;118:1971–81.
Mesguish C, Fardanesh R, Tanenbaum L, Chari A, Jaganath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18-FDG PET/CT according to Deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joint analysis of two prospective randomized Phase III trials. Blood. 2018;132(Suppl.):257.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.
Bladé J, Knop S, Cohen AD, Shah J, Meyer RM. Interpretation and application of the International Myeloma Working Group response criteria: proposal for uniform assessment and reporting in clinical trials based on the FIRST study independent review adjudication committee experience. Blood. 2014;124:3460.
Lee SE, Kim JH, Jeon YW, Yoon JH, Shin SH, Eom KS, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94:445–52.
Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020;105:193–200.
Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96:73–80.
Beksac M, Seval GC, Kanellias N, Coriu D, Rosiñol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105:201–8.
Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, et al. Hematogenous extramedullary relapse in multiple myeloma- a multicenter retrospective study in 127 patients. Am J Hematol. 2019;94:1132–40.
Bommer M, Kull M, Tleanu V, Schwarzwälder P, Feuring-Buske M, Kroenke J, et al. Leptomeningeal myelomatosis: a rare but devastating manifestation of multiple myeloma diagnosed using cytology, flow cytometry and fluorescent in situ hybridization. Acta Haematol. 2018;139:247–54.
Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, et al. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol. 2015;94:2033–42.
Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90:278–9.
Paubelle E, Coppo P, Garderet L, Azizi L, Bories D, Gorin NC, et al. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including haematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19:1702–4.
Rosiñol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade J, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76:405–8.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, et al. Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Hematol. 2016;172:89–96.
Zhou X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, et al. Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease. Cancers. 2020;12:1035.
Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017;177:221–5.
Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma; NPI 0052 101 Part 1. Blood. 2016;127:2693–700.
Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832–6.
Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma. 2001;42:683–7.
Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89–96.
Myers B, Grimley C, Crouch D, Dolan G. Lack of response to thalidomide in plasmacytomas. Br J Haematol. 2001;115:234.
Anagnostopoulos A, Gika D, Hamilos G, Zervas K, Zomas A, Pouli A, et al. Treatment of relapsed refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45:2275–9.
Jiménez-Segura R, Granell M, Gironella M, Abella E, García-Guiñón A, Oriol A, et al. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/refractory multiple myeloma. Eur J Hematol. 2019;102:389–94.
Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37–44.
Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, et al. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Ann Hematol. 2019;98:1435–40.
Beksac M, Richardson PG, Unal A, Corradini P, DeLimpasi S, Gulbas Z, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIA-MM subgroup analysis. EHA library 06/12/20;294895;EP978. Available at: https://library.ehaweb.org/eha/2020/eha25th/294895/meral.beksac.isatuximab.plus.pomalidomide.and.dexamethasone.in.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dicaria. Accessed January 2021.
Richardson PG, Mateos MV, Rodríguez-Otero P, Norkin M, Larocca A, Hassoun H, et al. Activity of melfufen in RR MM patients with extramedullary disease in the Phase 2 HORIZON study (OP-106): promising results in a high-risk population. Presented at the 17th International Myeloma Workshop 2019 (Boston), Oral presentation LBA 86. Clin Lymphoma Myeloma Leuk. 2019;19(Suppl.):E352–3.
Yee AJ, Huff AC, Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, et al. Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple class refractory myeloma who had plasmacytomas. Blood. 2019;134(Suppl 1):3140.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–28.
Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG SO777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.
Sonneveld P, Goldschmith H, Rosiñol L, et al. Bortezomib-based versus non-bortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279–87.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.
Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, et al. The Arkansas approach to therapy in patients with multiple myeloma. Best Pract Res. 2007;20:761–81.
Rosiñol L, Jiménez R, Rovira M, Martinez C, Fernandez-Aviles F, Marin P, et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant. 2015;15:658–62.
Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of international scoring system 3, high lactate dehidrogenase, and t(4;14) and or del (17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–80.
Cavo M, Golschmidt H, Rosiñol L, Pantani L, Zweegman S, Salwender HJ, et al. Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized Phase 3 studies. Blood. 2018;132(Suppl 1):124.
Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, et al. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regimen DT-PACE. Eur J Haematol. 2008;81:432–6.
Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U, et al. The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma. Ann Hematol. 2014;93:1207–14.
Isola I, Granell M, Martí Josep M, Gironella M, García-Guinón A, López-Pardo J, et al. PACE como tratamiento de rescate en pacientes con mieloma multiple recaído o refractario. Haematologica 2015;100:S4. 46# abstract CO-070.
Rodríguez-Lobato LG, Ganzetti M, Fernández de Larrea C, Hudecek M, Einsele H, Danhof S. CAR T-cells in multiple myeloma: state of the art and future directions. Front Oncol. 2020;10:1243.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.
Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, et al. BCMA-targeted CAR-T cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res. 2019;7:1047–53.
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor prognosis in relapsed multiple myeloma. J Clin Oncol. 2018;36:2267–80.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR-T cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR-T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210–21.
